No Data
Xianju Pharmaceutical to Set Up New Subsidiary
Zhejiang Xianju Pharmaceutical (002332.SZ) plans to establish a new subsidiary to undertake part of the Active Pharmaceutical Ingredient segment business.
Zhejiang Xianju Pharmaceutical (002332.SZ) announced that the company aims to improve management efficiency and enhance and optimize the Active Pharmaceutical Ingredient business...
Zhejiang Xianju Pharmaceutical (002332.SZ): The high-end formulation project has entered the equipment installation and debugging stage.
Gelonghui, December 23丨Zhejiang Xianju Pharmaceutical (002332.SZ) stated on the investor interactive platform that the high-end formulation project has entered the equipment installation and debugging stage. The company's goodwill was formed in the consolidated balance sheet after the acquisition of 100% equity of the Italian companies Newchem and Effechem in 2017.
The One-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Stock Falls a Further 9.4% in Past Week
Zhejiang Xianju Pharmaceutical (002332.SZ) intends for two products to be selected in the tenth batch of national Pharmaceutical centralized procurement.
Zhejiang Xianju Pharmaceutical (002332.SZ) announced that the company participated in the national organization on December 12, 2024...
Zhejiang Xianju Pharmaceutical (002332.SZ): Sugammadex Sodium Injection and Methionine Sulfate Neostigmine Injection are expected to be selected for centralized procurement.
Gelonghui, December 13th: Zhejiang Xianju Pharmaceutical (002332.SZ) announced that on December 12, 2024, the company participated in the bidding for the 10th batch of national centralized pharmaceutical procurement organized by the National Organization for Drug Procurement Office. The company's products, Sugengutong Sodium Injection and Methanesulfonate Neostigmine Injection, are intended to be selected for this centralized procurement.
Little Excitement Around Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Earnings As Shares Take 27% PoundingSee the daily top gainer.
